Autologous stem cells Medicine 09 January 2018 Extended indication Heart failure - advanced chronic, secondary to ischaemic cardiomyopathy Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Autologous stem cells Domain Cardiovascular diseases Reason of inclusion Main indication Heart failure Extended indication Heart failure - advanced chronic, secondary to ischaemic cardiomyopathy Current proprietary name Already available biosimilars / generics Proprietary name C-Cure Manufacturer Celyad Portfolio holder Mechanism of action Unknown Route of administration Intracardiac Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References www.volksgezondheidenzorg.info Additional remarks In 2015 waren er naar schatting 227.300 mensen bij wie de huisarts hartfalen heeft gesteld. Expected cost per patient per year Cost References Additional remarks Meerkosten Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks